Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States
Chadi Nabhan(University of Chicago), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), David L. Grinblatt(NorthShore University HealthSystem), E. Dawn Flick, Pavel Kiselev, Matthew S. Davids(Dana-Farber Cancer Institute), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Arlene S. Swern, Kristen Sullivan, Mark A. Weiss(Thomas Jefferson University), Shriya Bhushan, Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 13
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k